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Abstract
Background: Menkes disease (MD) is an X-linked, fatal neurodegenerative disorder of copper metabolism, caused
by mutations in the ATP7A gene. Thirty-three Menkes patients in whom no mutation had been detected with
standard diagnostic tools were screened for exon duplications in the ATP7A gene.
Methods: The ATP7A gene was screened for exon duplications using multiplex ligation-dependent probe
amplification (MLPA). The expression level of ATP7A was investigated by real-time PCR and detailed analysis of the
ATP7A mRNA was performed by RT-PCR followed by sequencing. In order to investigate whether the identified
duplicated fragments originated from a single or from two different X-chromosomes, polymorphic markers located
in the duplicated fragments were analyzed.
Results: Partial ATP7A gene duplication was identified in 20 unrelated patients including one patient with Occipital
Horn Syndrome (OHS). Duplications in the ATP7A gene are estimated from our material to be the disease causing
mutation in 4% of the Menkes disease patients. The duplicated regions consist of between 2 and 15 exons. In at
least one of the cases, the duplication was due to an intra-chromosomal event. Characterization of the ATP7A
mRNA transcripts in 11 patients revealed that the duplications were organized in tandem, in a head to tail
direction. The reading frame was disrupted in all 11 cases. Small amounts of wild-type transcript were found in all
patients as a result of exon-skipping events occurring in the duplicated regions. In the OHS patient with a
duplication of exon 3 and 4, the duplicated out-of-frame transcript coexists with an almost equally represented
wild-type transcript, presumably leading to the milder phenotype.
Conclusions: In general, patients with duplication of only 2 exons exhibit a milder phenotype as compared to
patients with duplication of more than 2 exons. This study provides insight into exon duplications in the ATP7A gene.
Background
Menkes disease (MD; MIM# 309400) is a multisystemic
lethal disorder of impaired copper metabolism due to
mutations in the X-linked ATP7A gene [1,2]. The disor-
der is transmitted in an X-linked recessive pattern. The
ATP7A protein is a member of the P-type ATPase
family that ensures the ATP-driven translocation of
metal cations across cellular membranes. The protein
plays a dual role: it is responsible for the copper-loading
of several copper-requiring enzymes, as well as for the
ATP-driven efflux of copper from the cell [3-5]. At nor-
mal physiological copper concentrations, ATP7A is
localized to the trans-Golgi network (TGN) [3] where
copper-loading of enzymes in the secretory pathway
takes place. In response to the increase in copper con-
centration, the protein is translocated to the plasma
membrane [3] where it is involved in pumping excess
copper out of the cell. In the human body, copper is
taken up in the gastrointestinal tract. However, patients
with MD are unable to transport copper further from
the intestinal cells, and less copper is therefore delivered
to the blood. These patients have severe developmental
and neurological impairments due to a sub-normal
amount of copper in the brain. In addition, a reduced
activity of several copper-dependent enzymes can lead
to a variety of symptoms such as connective tissue
abnormalities, tortuosity of blood vessels and peculiar
hair (kinky, steely hair or pili torti) [1,2]. The phenotypic
features of MD can be divided into at least three
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childhood, the less severe atypical MD with longer sur-
vival, and the mildest allelic form Occipital Horn Syn-
drome (OHS). The neurological symptoms of OHS
patients are milder than those found in patients with
atypical MD and lead to a clinical picture mainly char-
a c t e r i z e db yc o n n e c t i v et i s s u em a n i f e s t a t i o n s .T h e
majority of MD patients display the phenotype of classi-
cal MD, but milder phenotypes are seen in about 9% of
the patients, and approximately one third of these have
OHS [6].
To date, about 250 mutations in the ATP7A gene have
been reported and are partly registered in the Human
Mutation Database http://www.hgmd.org. Different
types of mutations have been described: cytogenetic visi-
ble chromosome aberration, point mutations (deletions,
insertions, missense and nonsense mutations, splice-site
mutations), gross deletions including one or several
exons [7], and more recently, exon duplications [8].
Traditional mutation-screening with PCR amplifica-
tion of the coding region of ATP7A (23 exons) followed
by sequencing, fails to detect exon duplications. In this
study, we identified exon duplications in 20 patients
using Multiplex ligation-dependent probe amplification
(MLPA), and we have carried out detailed analyses of
the ATP7A mRNA in 11 patients.
Patients and Methods
Patients
Thirty-three Menkes patients, in whom no mutation
c o u l db ei d e n t i f i e di nt h eATP7A gene (Genbank:
NP_000043.2) either by sequencing or by exon PCR [9],
were included in this study. The patients were referred
to the Kennedy Center between 1994 and 2006 by a
number of genetics centers in Europe and in USA for
molecular confirmation of the diagnosis. All 33 patients
had a well-documented clinical diagnosis of MD.
The patients (P7-P20) classified by the referring genet-
ics centers as patients with classical MD, have symp-
toms such as hypothermia, feeding difficulties,
convulsions, abnormal hair, dry skin, cutis laxa, hypopig-
mentation, bladder diverticula, cryptochidism, ataxia,
mental retardation, decreased serum copper, decreased
serum ceruloplasmin and abnormal radiographs. The
patients typically died before they were 3 years old.
The patients (P2, P3, P4 and P5) classified by the
referring genetics centers as patients with the atypical
form of MD have fewer symptoms, are more attentive
and interested in surroundings and survive longer. This
group of patients typically survived for at least seven
years.
One patient was classified by the referring genetics
center as having the OHS phenotype (P1). He is at the
time of writing 24 years old.
Multiplex Ligation-dependent Probe Amplification
Genomic DNA was extracted from either leucocytes or
cultured fibroblasts using standard methods. The MLPA
ATP7A kit “S A L S AM L P AP 1 0 4 ” was obtained from
MRC-Holland (Amsterdam, The Netherlands). The kit
contains probes for 22 exons of the ATP7A gene (no
probe was available against exon 23) as well as 11 con-
trol probes for other locations at the X-chromosome.
Details on probe sequences can be found at the com-
pany’s website http://www.mrc-holland.com. MLPA was
performed according to the manufacturer’sp r o t o c o l .
Reaction products were separated on an ABI model 310
capillary sequencer or an ABI3130XL sequencer
(Applied Biosystems, Foster, CA) and GeneScan 3.1 soft-
ware was used to size the PCR products and to obtain
relative peak areas (RPA) as described previously [10].
The RPA of each probe was determined by dividing the
peak area of each individual probe by the sum of the
peak areas of all the control probes obtained for that
sample. The RPA from each probe was then compared
to that of a control sample by dividing the RPA with the
RPA for the same probe obtained from a control sam-
ple, resulting in an RPA ratio. An RPA ratio of approxi-
mately 1 is normal whilst an RPA ratio of approximately
2 indicates a duplication of the exon.
Polymorphism analysis
For patients whose polymorphic markers were known to
be located in the duplicated fragments (from the size of
the duplicated fragment or from verification by Q-PCR,
see below), these markers were analyzed in order to
establish whether the fragments originated from a single
or from two different X-chromosomes. The regions con-
taining the polymorphic STR, CA repeat, G00-437-244
located in intron 5 [11], the SNP Rs2227291 located in
exon 10 [12], and a SNP in intron 13 (c. 2782-29C > A)
[12] respectively, were amplified by PCR in relevant
patients. The region containing the CA repeat was
amplified using the primer-pair; F: 5’gccaagtattatgaag-
caagg-3’/R: 5’-taccagtcttgaccccaaaca-3’.T h er e g i o nc o n -
taining the SNP in exon 10 was amplified using the
primer-pair; F: 5’-atatatgtgaatttcagcattttttaa-3’/R: 5’-atg-
tatttccaatgattggcc-3’ and the region containing the SNP
in intron 13 was amplified using the primer-pair; F: 5’–
caccacacctggccattaac-3’/R: 5’-tcactctcccactccaaacc-3’.
The PCR amplified fragments with the CA repeats were
analyzed in an ABI 3130XL followed by detection with
GeneMapper 3.0 Software (Applied Biosystems, Foster,
CA). The SNPs were analyzed by sequencing the ampli-
fied PCR products.
Q-PCR
Q-PCR was performed using genomic DNA (50 ng/sam-
ple). PCR amplification and detection was performed
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with the manufacturer’s instruction using SYBR-Green.
In patients P3, P6, and P7 the inclusion of the CA
repeat in the duplicated region was confirmed by Q-
PCR using primers located close to the position of the
CA repeat. In contrast, Q-PCR revealed that the CA
repeat was not included in the duplication in patient
P11. As the primer-pair used for amplification of the
CA repeat was not applicable for Q-PCR, the Q-PCR
was performed using the primer-pairs; F: 5’-tggagggtg-
taggaatgtatatgaaa-3’/R: 5’-tcaccttgcttcataatacttggcta-3’
and F: 5’-atacaacccccaatgatagcaga-3’/R: 5’-ggctccaaatc-
caagttctcg-3’ located upstream and downstream of the
CA repeats, respectively.
Cell cultures
Skin samples were collected from 11 patients, for diag-
nostic purposes. The fibroblasts were cultured as
described previously [13].
Characterization of ATP7A mRNA
Total RNA was isolated from approximately 5 × 10
6
cells of cultured skin fibroblasts with the RNAeasy Mini
Kit (Qiagen). Single-stranded cDNA was synthesized
with the High-Capacity cDNA Archive Kit (Applied Bio-
systems). The cDNA was used for PCR amplification
with ATP7A-specific primer pairs flanking the duplica-
tion of interest. We amplified the duplicated region
directly in 9 patients. The Advantage 2 PCR Kit (Clon-
tech) was used for the amplification. The products were
separated on a 1% agarose gel, and the fragments were
excised and purified (Qiaquick gel extraction kit, Qia-
gen) before sequencing with the PCR amplification pri-
mers. For two patients, we performed RT-PCR on the
duplication borders. For P10, who had a duplication of
exon 3_17, we used the primers 16U and 4L and for
P12, who had a duplication of exon 7_10, we used the
primers 10U and 8L.
Sequencing
The Big Dye Terminator v.3.1 Cycle Sequencing Kit was
used for sequencing, and the products were analyzed in
an ABI model 310 capillary sequencer.
Quantitative RT-PCR
Real-time PCR was performed for relative quantification
of the total amount of ATP7A transcript using probes
located outside the duplicated regions. Real-time PCR
amplification and detection were performed as described
previously [14]. Real-time PCR was performed on cDNA
obtained from patient- and control-fibroblasts. A Taq-
Man 6-carboxy-fluorescein (FAM) labeled probe and
primer pair against the boundary between exon 1 and
exon 2 (part number Hs00921963_m1) in the ATP7A
cDNA was used to detect ATP7A transcript. A FAM or
VIC (Applied biosystems proprietary dye) labeled probe
and primers for the human GAPDH transcript (part
number 4352934E and 4326317E respectively) were
used as an endogenous control. Relative quantification
of GAPDH transcript was carried out on parallel sam-
ples. RNA from fibroblasts obtained from each of the
patients was harvested two independent times. The
cDNA samples obtained from the two RNA prepara-
tions were assayed in the concentrations; 100 ng/sample
and 50 ng/sample respectively, in a total volume of 25
μl. Each dilution was assayed in triplicate. All probes
were purchased from Applied Biosystems. PCR amplifi-
cation and detection was performed with an ABI7300 or
ABI7500 (Applied Biosystems) in accordance with the
manufacturer’s instruction. The threshold cycle (CT)i s
defined as the fractional cycle number at which the
fluorescence passes a fixed threshold. Standard curves of
(CT) values compared with log cDNA concentration
were prepared by assaying five-fold serial dilutions of
control cDNA, from 100 ng/sample to 0.16 ng/sample,
with the GAPDH and ATP7A probes respectively.
Results
Thirty-three Menkes patients were analyzed for duplica-
tions by MLPA. Duplication of two or more contiguous
exons was found in 20 patients. The obtained results are
shown in Table 1. The detected duplicated regions con-
tained from 2 to 15 exons. Furthermore, results
obtained from 5 control samples including standard
deviation (SD) are illustrated in Figure 1. The pheno-
types of the 20 patients are ranked as 1) severe classical
form 2) milder atypical form with longer survival and 3)
OHS. The phenotypes and MLPA results are summar-
ized in Table 2. Notably, all patients with duplication of
only two exons (and known phenotypes) displayed atypi-
cal MD or OHS, whereas the patients with duplication
of a region with more than two exons all displayed clas-
sical MD. Unfortunately, the clinical phenotype is not
known for patient P6 who had a duplication of two
exons.
Source of the mutations
In order to test whether the observed duplications origi-
nated from two different X-chromosomes, polymorph-
ism markers located in the duplicated regions were
analyzed in selected patients and in the mothers of
patients with de novo mutations; P2, P10, and P19
(Table 3 and Materials and Methods). None of the
patients had different allelic variants at any of the inves-
tigated polymorphic sites. The mothers of P10
(3_17dup) and P19 (6_15dup) were both homozygous at
the investigated SNPs. In contrast, the mother of P2 was
found to be heterozygous at the CA repeat (Table 3).
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Exon/Patient C P1 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15* P16 P17 P18 P19 P20
Ex 1a 0.936 0.974 0.920 0.922 1.034 0.921 0.904 1.020 0.922 0.956 0.796 0.969 1.016 0.959 0.982 0.957 1.032 0.804 0.884 0.837 0.994
Ex 1b 0.934 0.970 0.903 0.945 0.938 0.953 1.010 1.061 0.903 0.991 0.856 1.030 1.015 0.943 0.998 0.943 0.904 1.032 0.851 0.960 0.959
Ex 2 1.005 0.992 1.014 1.071 1.014 1.045 0.971 1.006 0.968 0.991 0.859 1.001 1.012 1.002 1.030 0.908 0.974 0.885 0.983 1.000 0.963
Ex 3 0.954 1.905 0.975 1.042 1.021 1.006 1.012 1.765 0.861 1.752 1.717 0.973 1.021 0.946 1.017 0.985 0.999 0.969 0.924 0.979 0.954
Ex 4 1.028 2.009 1.024 1.155 1.052 1.009 1.076 1.910 1.088 1.878 1.903 0.848 1.033 0.956 0.997 0.956 0.995 1.125 1.024 0.979 1.002
Ex 5 0.990 0.944 1.841 1.011 0.971 1.014 1.082 1.889 1.686 1.880 1.662 0.915 0.932 0.952 1.170 0.946 0.904 1.030 0.948 0.987 0.948
Ex 6 0.953 0.964 1.914 2.096 0.934 0.939 1.884 1.000 1.813 1.850 1.723 1.725 0.983 0.949 1.030 0.961 1.012 0.941 0.882 1.009 0.933
Ex 7 1.017 0.931 0.988 1.960 0.943 1.011 1.925 0.981 1.688 1.860 1.629 1.827 2.339 1.874 1.879 1.305 1.011 0.946 0.912 0.971 0.935
Ex 8 0.950 1.050 1.000 0.748 1.014 1.015 1.034 0.990 1.010 1.854 1.980 1.723 2.908 1.943 1.845 1.343 1.943 2.346 1.786 1.845 1.884
Ex 9 0.990 1.049 1.035 1.057 1.021 1.026 1.032 0.970 1.062 1.937 1.884 1.762 2.904 2.055 2.010 1.330 1.994 1.985 1.769 1.873 1.789
Ex 10 0.903 1.020 1.031 0.872 1.003 0.968 0.993 1.023 0.977 1.816 1.834 1.742 2.845 1.917 1.772 1.536 1.875 1.989 1.860 1.883 1.633
Ex 11 1.031 0.979 1.024 1.000 1.004 0.970 1.094 1.024 1.058 1.800 1.847 1.842 0.990 1.855 1.911 1.455 1.842 2.119 1.636 1.930 1.936
Ex 12 1.060 1.032 1.032 1.069 1.070 1.013 1.037 1.000 1.014 1.870 1.564 1.962 1.032 1.644 2.234 1.211 1.762 1.703 2.118 1.858 1.761
Ex 13 1.058 1.068 1.041 1.148 1.907 0.855 1.104 1.095 0.988 1.635 1.756 2.901 1.025 1.014 1.199 1.290 1.034 0.909 1.995 1.846 1.838
Ex 14 1.000 0.989 1.010 0.978 1.649 1.034 1.184 1.005 0.979 0.907 1.853 2.569 0.949 0.973 1.196 1.345 0.942 1.203 1.969 1.886 1.910
Ex 15 1.040 1.026 0.988 0.806 1.024 0.938 1.031 0.972 1.008 0.950 1.717 1.996 1.022 0.981 1.042 0.995 1.088 0.940 1.053 1.907 1.855
Ex 16 0.998 1.095 1.043 1.031 1.050 1.946 1.066 0.967 0.980 0.990 1.687 0.943 1.054 1.075 0.995 1.075 1.102 0.905 0.862 1.029 1.721
Ex 17 0.997 0.990 0.965 0.963 1.003 1.786 1.007 0.993 0.958 0.975 1.686 0.834 0.964 0.960 1.042 0.920 1.012 0.926 0.930 0.990 1.861
Ex 18 0.994 1.017 0.972 1.019 0.978 0.964 1.160 0.984 0.991 0.936 0.949 0.874 1.002 1.009 0.922 1.009 0.984 1.120 0.915 0.999 0.942
Ex 19 0.964 1.035 1.030 1.128 1.036 0.983 0.061 1.003 1.041 1.006 0.934 0.904 1.045 1.008 1.088 1.008 1.073 0.946 0.962 0.990 0.904
Ex 20 0.976 0.957 0.991 0.825 0.981 0.986 0.912 0.990 0.979 0.917 0.921 0.918 1.008 1.018 1.057 0.925 0.993 0.980 0.729 0.993 0.924
Ex 21 0.977 1.054 1.035 0.866 1.066 1.011 1.001 0.959 0.961 0.950 0.905 0.910 1.044 1.064 1.120 1.064 1.003 0.928 0.775 0.995 0.957
Ex 22 0.968 0.963 0.927 1.059 0.985 0.930 1.154 0.994 0.974 1.002 0.907 0.952 0.970 0.949 1.164 0.904 0.959 1.072 1.152 0.956 0.945
RPA ratios for the ATP7A located MLPA probes in a control (C) and the 20 patient DNA samples (P1-P20). The MLPA kit include in addition 11 control probes (not shown in the figure) located at other positions of the
X-chromosome.
*The mother of the index patient is tested.
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1Characterization of the ATP7A transcripts in the patients
The exact location and orientation of the duplicated
exons were established by analyzing the ATP7A tran-
scripts in cultured fibroblast from eleven selected
patients. Fragments that spanned the individual duplica-
tions were amplified by RT-PCR using primer-pairs
flanking the duplications (Table 4). RNA from five
patients with a duplicated region containing only 2
exons (Figure 2A) and from four patients with duplica-
tion of more than two exons was investigated (Figure
2B, C). Several transcripts of different sizes were
observed in all patients (Figure 2). The size of the lar-
gest transcript was in all patients, larger than the tran-
script obtained from control samples, and the difference
in size corresponds to the expected size of the duplica-
tion. When sequencing the largest transcript in the 9
patients, we found -in all patients- that they contain the
duplicated exons and that the duplicated part of the
ATP7A gene was arranged in tandem, head to tail, with
t h eo r i g i n a lc o p y( T a b l e5 ) .T h ed u p l i c a t e de x o n sw e r e
incorporated in the final ATP7A transcript at the nor-
mal splice sites, and in all 9 patients the duplication dis-
rupted the translational reading frame. For two patients,
RT-PCR analysis was carried out with special focus on
the duplication borders. cDNA from P10 with a duplica-
tion of exon 3-17 was investigated with the primer-pair
16U/4L and cDNA from P12 with a duplication of exon
7-10 was investigated with the primer-pair 10U/8L
(Table 4). Sequencing of the amplified fragments (P10:
ex16-ex17-ex3-ex4, and P12: ex10-ex7-ex8) revealed
that the duplications also in these two patients were in
tandem head to tail (not shown). PCR amplification of
control cDNA with the two primer pairs (16U/4L and
10U/8L), did as expected, not lead to the formation of
any PCR product, as a borderline between exon 17 and
exon 3 and a borderline between exon 10 and exon 7
only was present in P10 and P12, respectively.
In all patients a transcript of similar size as the wild-
type ATP7A transcript was visible (Figure 2). In patient
P1 with OHS, this product accounted for a substantial
fraction of the total amount of transcript (Figure 2A). In
the other patients a faint -in some cases almost invisi-
ble- band corresponding to the wild-type transcript
could be observed (Figure 2). There was enough product
to perform sequencing in all cases, and the sequencing
confirmed that the bands indeed were wild-type tran-
script. Thus wild-type transcript is expressed in all
patients. When sequencing PCR-amplified fractions of
the different smaller transcripts obtained from the
patients, we found that several exon-skipping events
occurred within the duplicated regions (Table 5). In
some splicing variants the reading frame was intact,
while in others it was disrupted.
Relative quantification of ATP7A transcript in patient cells
The ordinary RT-PCR (Figure 2) is not quantitative.
Therefore, the relative amount of total ATP7A transcript
was determined by real-time PCR with probes that recog-
nized an exon-exon junction located outside the dupli-
cated region. In order to normalize any differences in the
cDNA-input in the samples, a probe that detected the
housekeeping gene, GAPDH, was used as an endogenous
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Figure 1 Barchart of the MLPA results. The results are presented as the mean RPA ratio of each exon, obtained from five healthy controls.
The error bars represents the standard deviation.
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Page 5 of 11control (Figure 3). The total amount of ATP7A transcript
varied from 8% to 22% of the amount found in the normal
control sample. The patient with the highest amount of
transcript (22%) had atypical MD. Otherwise, there was no
clear difference between the total amounts of transcripts
in patients with OHS or atypical phenotypes, and patients
with classical phenotypes. The total amount of ATP7A
transcript is in all patients low relative to the healthy con-
trol, and is difficult to quantify exactly. The obtained CT
values were between 29 and 31 indicating a copy number
between 10
3 and 10
2 per sample.
Discussion
MLPA was used to test for any evidence of duplications in
the ATP7A gene in 33 Menkes patients in whom no muta-
tion had been detected with standard diagnostic tools. Five
controls were additionally assayed with the MLPA assay
and the results showed very little variation between indivi-
duals (Figure 1). This in turn demonstrates the robustness
of the MLPA technique in copy-number determination.
We identified exon duplications in 20 of the patients. This
corresponds to a duplication frequency of approximately
4% for the combined cohort of 468 independent Menkes
Table 2 Exon duplications identified in the ATP7A gene
Patient
(reference
number)
Duplication:Mutation
(identified on genomic DNA)
Phenotype Mutation origin
P1 (95287) Ex3_4dup:
c.121-?_1336+?dup
OHS Unknown
P2 (96220) Ex5_6dup:
c.1337-?_1707+?dup
Atypical De novo
P3 (93250) Ex6_7dup:
c.1544-?_1869+?dup
Atypical Mother carrier
P4 (9926) Ex 13_14dup:
c.2627-?_2916+?dup
Atypical Mother carrier
P5 (96267) Ex16_17dup:
c.3112-?_3511+?dup
Atypical Unknown
P6 (92251) Ex6_7dup:
c.1544-?_1869+?dup
Unknown clinical phenotype Unknown
P7(95288) Ex3_5dup:
c.121-?_1543+?dup
Classical Unknown
P8 (95265) Ex5_7dup:
c.1337-?_1869+?dup
Classical Unknown
P9 (93226) Ex3_13dup:
c.121-?_2781+?dup
Classical Mother carrier
P10 (96205) Ex3_17dup:
c.121-?_3511+?dup
Classical De novo
P11 (94249) Ex6_15dup:
c.1544-?_3111+?dup
Classical Mother carrier
P12 (94253) Ex7_10 dup:
c.1708-?_2406+?dup
Classical Unknown
P13 (95245) Ex7_12dup:
c.1708-?_2626+?dup
Classical Unknown
P14 (91211) Ex7_12 dup:
c.1708-?_2626+?dup
Classical Unknown
P15 (93261) Ex7_14 dup:
c.1708-?_2916+?dup
Classical Mother carrier
P16 (91212) Ex8_12dup:
c.1870-?_2626+?dup
Classical Mother carrier
P17 (9620) Ex 8_12 dup:
c.1870-?_2626+?dup
Classical Mother carrier
P18 (92238) Ex8_14dup:
c.1870-?_2916+?dup
Classical Unknown
P19 (9322) Ex8_15dup:
c.1870-?_3111+?dup
Classical De novo
P20 (96291) Ex8_17dup:
c.1870-?_3511+?dup
Classical Mother carrier
Summary of exon duplications identified in the 20 patients.
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who has been referred to the Kennedy Center [15]. In
comparison, the estimated frequency of deletions in the
ATP7A gene in almost the same cohort of patients is 17%
[6]. No mutation could be identified by MLPA in 13 of the
investigated Menkes patients. It is possible that they con-
tain a mutation in the regions of the ATP7A gene not
investigated, such as the intronic sequences, the promoter
or the 3’-UTR sequence. The copper excreting ability of
fibroblast from 11 of the 13 males were analysed and the
obtained results were in all cases in agreement with
Menkes disease.
In three of the patients-P2, P10 and P19-the duplica-
tions seemed to be de novo mutations, only present in
the somatic cells of the affected male (although germline
mutations in the mother cannot be ruled out). Eight of
the patients had inherited the duplication from the
mother. It was not possible to obtain DNA from the
mothers of the last 9 patients.
T h ep r e s e n c eo ft h es a m ea l l e l i cv a r i a n to ft h eG 0 0 -
437-244 marker in P2 combined with the heterozygosity
in the mother of P2, indicate that the duplicated frag-
m e n tw a sd e r i v e df r o mt h es a m ec h r o m o s o m ea sa
result of an intra-chromosomal event. How the duplica-
tions in the rest of the patients occurred is unknown.
H o w e v e r ,t h ep r e s e n c eo ft h es a m ea l l e l i cp o l y m o r p h i c
variant in the duplicated regions in all the investigated
patients could suggest that the duplicated fragments in
these patients as well, are derived from the same
chromosome.
Table 3 Investigation of polymorphism in the duplicated regions
Location Polymorphism analysed Type SNP/STR
Intron 5 CA5 (G00-437-244) (Genome data base) STR
OH: (0.600)
#
Size of PCR fragment, copy 1/copy 2:
P2 (de novo): 176/176
P2 Mother: 176/180 (heterozygous)
P3: 182/182
P6: 180/180
P7: 182/182
P8: 182/182
Exon 10 Rs2227291 (NCBI), c.2299 G > C SNP
OH: 0.599 (NCBI)
Nuclotide at position c.2299:
P9: G/G
P10 (de novo):G/G; P10 Mother: G/G (homozygous)
P19 (de novo): G/G; P19 Mother: G/G (homozygous)
P11: G/G
P17: G/G
P18: G/G
P13, P14, P15, P16, and P20: All C/C
Intron 13 c.2782-29C > A (IVS13-29C > A) SNP
OH: Unknown
Nucleotide at position c.2782-29:
P9: C/C
P10 (de novo):C/C; P10 Mother: C/C (homozygous)
P19 (de novo); P19 Mother: C/C (homozygous)
P20: C/C
P4, P11 and P15: All A/A
Selected patients (and their respective mothers) were investigated for polymorphism at a polymorphic CA repeat (STR) and at two polymorphic SNPs located in
the duplicated regions. STR: short tandem repeat; SNP: single nucleotide polymorphism. Observed heterozygosity frequencies (OH).
# ref [11].
Table 4 Primers used for spanning the duplicated cDNA fragments
Patient Forward primer
(5’ to 3’ direction)
Reverse primer
(5’ to 3’ direction)
P1: Ex3_4dup 2U:atggatccaagtatgggtgtga 6L:tcacagtggctccaaatccaag
P2: Ex5_6dup 4U:caaaaagcagcccaagtacctc 7L:tattttatgtacgcaggaggc
P3: Ex6_7dup 5U:acacgaatgagccgttggtagt 10L:ggtggttgccagcacaatcagtacgtcc
P4: Ex13_14dup 12U:aggaggcaaatttccagtgga 15L:cagggacatgcaatacacagaactg
P5: Ex16_17dup 15U:tcccgaacagaaacgataatacga 19L:tctagctgttttactgttgtctccagt
P7: Ex3_5dup 2U:atggatccaagtatgggtgtga 7L:tattttatgtacgcaggaggc
P8: Ex5_7dup 4U:caaaaagcagcccaagtacctc 10L:ggtggttgccagcacaatcagtacgtcc
P13: Ex7_12dup 6U:gtgatagaaaatgctgatgaa 12L:ctggaaatttgcctcctggaact
P16: Ex8-12dup 7U:cctggcaaccaacaaagcaca 15L:ttcagcagttcccacaatgg
P10: Ex3_17dup 16U: ccattgtgggaactgctgaaagtaac 4L: cctttgctgtgacccttctg
P12: Ex7_10dup 10U: acgtactgattgtgctggcaac 8L: aagaccgtctccattgtcttattt
The sequence of primers used for spanning the duplicated cDNA fragments in selected patients.
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Page 7 of 11Several mechanisms that lead to duplications have
been proposed for those identified in other diseases,
such as Duchenne muscular dystrophy gene: homolo-
gous and non-homologous unequal chromatid exchange
by recombination and synthesis-dependent non-homolo-
gous end joining [16,17]. In homologous recombination,
sequence homology between the two parental DNA
strands in the crossover is required for strand exchange.
Homologous recombination could occur between repeti-
tive elements in different introns of the gene.
The tandem duplications create one duplication junc-
tion flanked by two sequences which are normally sepa-
rated in the genome. The junctions seem to be located
at the border between two different intronic sequences;
t h ei n t r o n i cs e q u e n c ed o w n s t r e a mo ft h ef i r s tc o p ya n d
the intronic sequence upstream of the second copy of
the duplicated fragment. We found that 40% (8/20) of
the ATP7A duplication breakpoints are located in intron
7. Furthermore, 25% (5/20) of the duplication break-
points are located in intron 6 and another 25% (5/20)
are located in intron 12. In total, 12 different introns are
involved in the duplications presented here, and in all
cases, the two involved introns have repeat regions in
common. Using the online bio-informatics tool http://
zeus2.itb.cnr.it/cgi-bin/wwwrepeat.pl we found that the
majority of these repeats are of the Alu or SVA type.
Interestingly, introns 3, 8, and 20 do not contain any
repeats, and there are no duplication junctions in any of
these introns. As the duplication junctions have not
been sequenced in order to verify whether there is any
significant sequence homology around the junctions or
if any nucleotides are inserted at the junction, it is
unknown how the duplications in ATP7A occur. Further
characterization of the duplication junctions might
reveal the mechanisms.
RT-PCR results from 9 selected MD patients revealed
that all the ATP7A transcripts that contain the duplica-
tions are out of frame, which leads to the formation of
premature termination codons. None of these transcripts
are expected to encode functional ATP7A protein, but
are probably degraded by the nonsense-mediated decay
(NMD) mechanism [18]. This concurs with the reduced
amount of transcript observed in all patients (Figure 3).
Patient P1, with an Ex3_4dup is diagnosed with OHS.
Until now about 14 patients with OHS have been
reported [6,8,19]. We have previously identified an
3000 bp
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600 bp
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A
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Figure 2 Investigation of cDNA obtained from patients (P). A: Patients with duplication of 2 exons and atypical MD (P2; P3; P4 and P5) or
OHS (P1) phenotypes. B and C: Patients with duplication of a region containing more than 2 exons and classical MD. The cDNA fragments
expected to contain the duplicated exons were amplified by PCR (see Materials and Methods). The corresponding fragments from a control cell
culture (C) were investigated in parallel. Hyperladder I was used as a marker (M).
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Page 8 of 11Ex3_4del in a patient with MD with unexpectedly mild
symptoms and long survival. The mutated transcript in
this patient contains a premature termination codon
after only 46 codons. We verified that the mild pheno-
type was due to the synthesis of, at least partially, func-
tional Menkes protein as a result of re-initiation at
internal ATG codons located in exon 5 [14]. As the
transcript in P1 does not contain a premature termina-
tion codon until codon 458, it is unlikely that reinitia-
tion takes place in this patient. It is more likely that the
OHS-phenotype in P1 is attributed to a relatively large
amount of wild-type transcript. P1 has approximately
12% total ATP7A transcript relative to the control level,
and according to Figure 2, a relatively large fraction of
this is wild-type transcript.
Wild-type transcript is observed in all patients. How-
ever, the exact amount of wild-type transcript is difficult
to determine. We have previously shown that 2-5%
wild-type transcript relative to the control level is suffi-
cient to allow the development of the mildest pheno-
t y p e - O H S[ 1 3 ] .I ti sp o s s i b l et h a te v e nl e s st r a n s c r i p ti s
sufficient to permit the development of atypical MD.
Thus, it is possible that at least a fraction of the other
patients with duplication of only two exons have atypical
MD phenotypes because of the presence of a small
amount of wild-type transcript. Recently, four duplica-
tions in the ATP7A gene, identified in MD patients,
have been published: Ex3_5dup, Ex2_4dup, Ex8_12dup
and Ex8-17dup [8]. The four duplications were all iden-
tified in patients with classical MD [8]. Three of the
four duplications, Ex3_5dup, Ex8_12dup and Ex8-17dup
were also identified in our cohort of patients.
Conclusions
In conclusion, we demonstrate that duplications in the
ATP7A gene were organized in tandem, in a head to tail
Table 5 PCR products obtained by spanning
Transcripts in patients with atypical MD or OHS.
Patient Transcripts Predicted effect on reading frame
P 1: Ex3_4dup I: 2-3-4-3-4-5 I:Out of reading frame
II:2-3-4-4-5 II: In reading frame
III:2-3-4-5 III: wild-type
P2: Ex5_6dup I: 4-5-6-5-6-7 I:Out of reading frame
II:4-5-6-7 II: wild-type
P3: Ex6_7dup I:5-6-7-6-7-8 I:Out of reading frame
II:5-6-6-7-8 II:Out of reading frame
III:5-6-7-8 III: wild-type
P 4: Ex13_14dup I:12-13-14-13-14-15 I:Out of reading frame
II:12-13-14-14-15 II:In reading frame
III:12-13-14-15 III: wild-type
P5: Ex16_17dup I:15-16-17-16-17-18 I:Out of reading frame
II:15-16-16-17-18 II:In reading frame
III:15-16-17-18 III: wild-type
Transcripts in patients with Classic MD.
Patient Transcripts Predicted effect on reading frame
P7: Ex3_5dup I: 2-3-4-5-3-4-5-6 I:Out of reading frame
II:2-3-4-5-5-6 II: In reading frame
III:2-3-4-5 III: wild-type
P8: Ex5_7dup I: 4-5-6-7-5-6-7-8-9 I:Out of reading frame
II:6-7-8-9 II: wild-type
P13: Ex7_12dup I:7-8-9-10-11-12-7-8-9-10-11-12-13-14 I:Out of reading frame
II: 7-8-9-10-8-9-10-11-12 II:In reading frame
III: 7-8-9-10-11-12 III: wild-type
P16: Ex8_12dup I:7-8-9-10-11-12-8-9-10-11-12-13-14 I:Out of reading frame
II: 7-8-9-10-8-9-10-11-12-13-14 II:In reading frame
III: 7-8-9-10-10-11-12-13-14 III:In reading frame
IV: 7-8-9-10-11-12-13-14 IV: wild-type
The different PCR products were isolated from the gels shown in Figure 2, and sequenced. The various transcripts are indicated by roman numerals. Arabic
numerals refer to the exons contained in the respective PCR products. The predicted effects on the reading frame are indicated.
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Page 9 of 11direction, and we suggest that the development of OHS
and the atypical MD phenotype is at least partly due to
the fact that the splicing apparatus by-passes the dupli-
cated region, leading to the production of wild-type
transcript.
List of abbreviations
MD: Menkes disease; NMD: nonsense-mediated decay; TGN: trans-Golgi
network; OHS: Occipital Horn Syndrome; MLPA: Multiplex ligation-dependent
probe amplification; RPA: relative peak areas.
Acknowledgements
We thank Jette Bune Rasmussen for her photographic help, Susan Peters for
the English language revision and Tina Christoffersen for her excellent
technical assistance. Colleagues who referred the patients, clinical data,
blood samples and skin biopsies to our laboratory for routine diagnosis are
acknowledged. A special thank to Nobuhiko Ochi for valuable clinical
information (P1).
Author details
1Center for Applied Human Molecular Genetics, Kennedy Center, Gl.
Landevej 7, 2600 Glostrup Denmark.
2Department of Health and Dietetics,
Faculty of Health and Medical Sciences, Teikyo Heise University, 2-51-4
Higashiikebukuro, Toshima-ku, Tokyo 170-8445, Japan.
3Departments of
Pediatrics and Neurology, Comer Childrens Hospital, University of
Chicago5841 South Maryland Ave. Chicago, Illinois, USA.
Authors’ contributions
Generation and analysis of the clinical data: HK, KS, NH, LBM. Mutation
identification and Real-Time PCR: MM, LBM, TS. Investigation of
polymorphisms and Q-PCR: LBM. RT-PCR: MM. Study concept: LBM.
Manuscript draft: LBM. Substantial participation in the design of the project
and writing the paper: LBM, TS, NH. All authors participated in the writing of
this paper in the context of their individual expertise, and all have read and
approved the final version of the article.
Competing interests
The authors declare that they have no competing interests.
Received: 23 May 2011 Accepted: 10 November 2011
Published: 10 November 2011
References
1. Menkes H, Alter M, Steigleder GK, Weakley DR, Sung JH: A sex-linked
recessive disorder with retardation of growth, peculiar hair, and focal
cerebral and cerebellar degeneration. Pediatrics 1962, 29:764-779.
2. Kodama H, Murata Y: Molecular genetics and pathophysiology of Menkes
disease. Pediatr Int 1999, 41:430-435.
3. Petris MJ, Mercer JF, Culvenor JG, Lockhardt P, Gleeson PA, Camakaris J:
Ligand-regulated transport of the Menkes copper P-type ATPase efflux
pump from the Golgi apparatus to the plasma membrane: a novel
mechanism of regulated trafficking. EMBO J 1996, 15:6084-6095.
4. Petris MJ, Strausak D, Mercer JF: The Menkes copper transporter is
required for the activation of tyrosinase. Hum Mol Genet 2000,
9:2845-2851.
5. Voskoboinik I, Brooks H, Smith S, Shen P, Camakaris J: ATP-dependent
copper transport by the Menkes protein in membrane vesicles isolated
from cultured Chinese hamster ovary cells. FEBS lett 1998, 435:178-182.
6. Møller LB, Mogensen M, Horn N: Molecular diagnosis of Menkes disease:
genotype-phenotype correlation. Biochimie 2009, 91:1273-1277.
7. Tümer Z, Birk Møller L, Horn N: Screening of 383 unrelated patients
affected with Menkes disease and finding of 57 gross deletions in
ATP7A. Hum Mutat 2003, 22:457-464.
8. Moizard MP, Ronce N, Blesson S, Bieth E, Burglen L, Mignot C,
Mortemouseque I, Marmin N, Dessay B, Danesino C, Feillet F, Castelnau P,
Toutain A, Moraine C, Raynaud M: Twenty-five novel mutations including
duplications in the ATP7A gene. Clin Genet 2011, 79:243-253.
100
12 8 10 11
22
9 10 9
14
0
20
40
60
80
100
120
P1 P2 P3 P4 P5 P7 P8 P13 P16
R
e
l
a
t
i
v
e
 
A
T
P
7
A
 
e
x
p
r
e
s
s
i
o
n
Patients
Figure 3 ATP7A mRNA expression in the patients. Barchart showing the relative ATP7A mRNA expression in 9 patients, compared to control
fibroblasts with a defined value of 100. The analysis has, for each patient, been performed on cDNAs from two different RNA preparations. The
amount of GAPDH transcript was used as a normalization reference. The samples were analysed in triplicates. In all experiments, the amounts of
ATP7A and GAPDH mRNA were calculated by linear regression of the lines generated by the standard curves; log cDNA concentration against CT
(see Materials and Methods). The presented results show the mean value of the two cDNA preparations. Error bars represents the standard
deviation of the results obtained from the two RNA preparations. The normalized ATP7AN value was calculated by dividing the ATP7A mRNA
value by the GAPDH mRNA value in parallel samples. The value relative to unaffected control fibroblasts was calculated by dividing the
normalized ATP7AN value from each patient by the normalized ATP7AN value obtained from control fibroblasts. The average ATP7A expression
from fibroblasts from four independent healthy individuals (controls) is presented in the grey bar.
Mogensen et al. Orphanet Journal of Rare Diseases 2011, 6:73
http://www.ojrd.com/content/6/1/73
Page 10 of 119. Poulsen L, Horn N, Heilstrup H, Lund C, Tümer Z, Møller LB: X-linked
recessive Menkes disease: identification of partial gene deletions in
affected males. Clin.Genet 2002, 62:449-457.
10. Møller LB, Nygren AO, Scott P, Hougaard P, Bieber Nielsen J, Hartmann C,
Güttler F, Tyfield L, Zschocke J: Low proportion of whole exon deletions
causing phenylketonuria in Denmark and Germany. Hum Mutat 2007,
28:207-212.
11. Begy CR, Dierick HA, Innis JW, Glover TW: Two highly polymorphic CA
repeats in the Menkes gene (ATP7A). Hum Genet 1995, 96:355-356.
12. Poulsen L, Horn N, Møller LB: X-linked recessive Menkes disease: Carrier
detection in the case of a partial gene deletion. Clin Genet 2002,
62:440-448.
13. Møller LB, Tümer Z, Lund C, Petersen C, Cole T, Hanusch R, Seidel J,
Jensen RL, Horn N: Similar splicing mutations of the ATP7A gene lead to
different phenotypes: Classical Menkes disease or Occipital horn
syndrome. Am J Hum Genet 2002, 66:1211-1220.
14. Paulsen M, Lund C, Akram Z, Winther JR, Horn N, Møller LB: Evidence that
translation reinitiation leads to a partially functional Menkes protein
containing two copper-binding sites. Am J Hum Genet 2006, 79:214-219.
15. Gourdon P, Liu X-Y, Skjørringe T, Morth JP, Møller LB, Pedersen BP, Nissen P:
Crystal structure of the copper pump. Nature 2011, 475(7354):59-64.
16. Hu X, Ray PN, Worton RG: Mechanisms of tandem duplication in the
Duchenne muscular dystophy gene include both homologous and
nonhomologous intrachromosomal recombination. EMBO J 1991,
10:2471-2477.
17. White SJ, Aartsma-Rus A, Flanigan KM, Weiss RB, Kneppers ALJ, Lalic T,
Janson AAM, Ginjaar HB, Breuning MH, den Dunnen JT: Duplications in the
DMD gene. Hum Mutat 2006, 27:938-945.
18. Hu X, Worton RG: Partial gene duplication as a cause of human disease.
Hum Mutat 1992, 1:3-12.
19. Maquat LE: When cells stop making sense: Effects of nonsense codons
on RNA metabolism in vertebrate cells. RNA 1995, 1:453-46.
20. Skjørringe T, Tümer Z, Møller LB: Splice site Mutations in the ATP7A gene.
Plos One 2011, 6:e18599.
doi:10.1186/1750-1172-6-73
Cite this article as: Mogensen et al.: Exon duplications in the ATP7A
gene: Frequency and Transcriptional Behaviour. Orphanet Journal of Rare
Diseases 2011 6:73.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
Mogensen et al. Orphanet Journal of Rare Diseases 2011, 6:73
http://www.ojrd.com/content/6/1/73
Page 11 of 11